Furosemide (Frusemide)
Related Subjects:
|Hypertension
|Acute Heart Failure
|Chronic Heart FailureLoop Diuretics
|
Entresto Sacubitril with Valsartan
|
Ivabradine
|
Furosemide
|
Angiotensin Converting Enzyme Inhibitors
|
Cardiac Resynchronisation Therapy (CRT) Pacemaker
|
๐ง Loop diuretics such as Furosemide are powerful agents for rapid fluid removal. Their effect is dose-dependent and may be reduced in severe renal failure - sometimes requiring very high doses or continuous infusion. โ ๏ธ Do not use long-term for simple gravitational oedema; this usually responds to leg elevation, compression stockings, and improved mobility. Always ๐ check the BNF entry here for up-to-date dosing and cautions.
๐งฌ Chemistry & Class
- Class: Loop diuretic (high-ceiling diuretic).
- Chemical name: 4-chloro-N-furfuryl-5-sulfamoylanthranilic acid (an anthranilic acid derivative).
- Highly protein bound (โ95%) โ secretion into tubular lumen depends on active transport rather than glomerular filtration.
โ๏ธ Mode of Action
- Inhibits the Naโบ/Kโบ/2Clโป cotransporter (NKCC2) in the thick ascending limb of the loop of Henle.
- Blocks reabsorption of sodium, chloride, and potassium โ osmotic water loss and increased urine output.
- Also enhances calcium and magnesium excretion.
- Venodilatory effect precedes diuresis (useful in acute pulmonary oedema to reduce preload).
- Dependent on renal blood flow - less effective in severe renal impairment unless very high doses or IV infusion used.
๐ Indications / Typical Doses
- Congestive cardiac failure (CCF/LVF): 20โ80 mg OD/BD PO (titrate to response).
- Acute pulmonary oedema: 40โ100 mg IV bolus over 20 mins, may repeat or switch to infusion if refractory.
- Chronic kidney disease: may require doses up to 250 mg/day or more (under specialist guidance).
- Hypertension: usually 20โ40 mg OD PO, often with ACE inhibitor or ARB.
- Mild peripheral oedema: 20โ40 mg OD PO or alternate days; combine with non-pharmacological measures (elevate legs, stockings, ambulation).
๐ Dose Range (check BNF / SPC)
| Indication | Typical Dose | Frequency | Route |
| Acute Pulmonary Oedema | 40โ100 mg | Stat | IV slow bolus over 20 mins |
| Decompensated Heart Failure | Up to 150 mg (max 1.5 g/day) | As infusion | IV over 3 hours |
| Chronic Heart Failure / CKD | 20โ80 mg | OD or BD (8am/1pm) | PO |
| Hypertension | 20โ40 mg | OD | PO |
๐ง Clinical Use & Pearls
- Give oral doses in the morning (and early afternoon if BD) to avoid nocturia.
- In acute LVF, venodilation provides rapid symptom relief even before diuresis begins.
- In advanced CKD, combine with a thiazide-type diuretic (e.g., metolazone) for synergistic effect - monitor closely for hypovolaemia and electrolyte loss.
- Always reassess the cause of oedema; chronic loop diuretic use without indication can worsen renal perfusion and cause hypotension.
โ ๏ธ Contraindications & Precautions
- Avoid with ototoxic agents (e.g., aminoglycosides, cisplatin) - additive hearing loss risk.
- Monitor renal function (U&E, eGFR) and electrolytes - risk of AKI and hypokalaemia.
- Severe hypovolaemia or hypotension โ hold until corrected.
- Hypokalaemia potentiates digoxin toxicity.
- Hypomagnesaemia and hypocalcaemia may cause arrhythmias.
๐ข Side Effects
- Circulatory: volume depletion, orthostatic hypotension โ syncope and falls (especially elderly).
- Electrolyte disturbances: โKโบ, โMgยฒโบ, โCaยฒโบ, โuric acid (gout), โglucose.
- Renal: pre-renal AKI, azotaemia, urinary retention (especially with prostate enlargement).
- Auditory: tinnitus and ototoxicity (esp. with high IV doses or aminoglycosides). In most cases, furosemide-induced ototoxicity is transient and reversible once the drug is stopped or the dose reduced. Hearing typically improves over hours to a few days. Furosemide inhibits NKCC transporters in the stria vascularis, disrupting the endocochlear potential. A rapid rise in plasma concentration causes an abrupt drop in cochlear potassium recycling. A slow infusion produces lower peak cochlear exposure even if the total dose is the same - so toxicity is much less likely.
- Endocrine/metabolic: hyperglycaemia, dyslipidaemia, gynaecomastia (rare cross-reactivity).
๐ค Drug Interactions
- Digoxin: โ toxicity due to hypokalaemia.
- ACE inhibitors/ARBs: โ risk of first-dose hypotension and renal dysfunction - monitor U&E.
- Lithium: โ clearance โ lithium toxicity.
- NSAIDs: blunt diuretic response and โ nephrotoxicity (โtriple whammyโ with ACEi/ARB).
- Ototoxic drugs: aminoglycosides, vancomycin, cisplatin โ additive auditory damage.
๐งฎ Monitoring
- Before starting: baseline U&E, eGFR, BP, weight, urine output.
- During treatment: monitor electrolytes (esp. Kโบ, Naโบ, Mgยฒโบ) daily if IV, every few days if PO.
- Ongoing: weight trends and clinical response - aim for 0.5โ1 kg/day fluid loss in acute overload.
- Check hearing if high-dose IV or prolonged infusion used.
๐ References
- BNF: Furosemide
- NICE NG106: Chronic heart failure in adults โ management.
- NICE NG28: Type 2 diabetes in adults โ diuretic therapy in hypertension/CKD.
- Renal Association 2024: Diuretic use in CKD guidelines.